The FDA’s decision this week to allow convalescent plasma as a treatment for COVID-19 will make it harder to conduct rigorous studies of its effectiveness, because patients will demand the therapy rather than agreeing to studies in which they might get a placebo, experts said Monday.
from The Boston Globe https://ift.tt/2Qn83aY
Felice J. Freyer
The FDA’s decision this week to allow convalescent plasma as a treatment for COVID-19 will make it harder to conduct rigorous studies of its effectiveness, because patients will demand the therapy rather than agreeing to studies in which they might get a placebo, experts said Monday.
https://ift.tt/3aXggvY August 25, 2020 at 01:47AM
ليست هناك تعليقات:
إرسال تعليق